Drug intelligence / Profile preview

MEDI3414

Development stage: Phase 4
Lead developer: AstraZeneca
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

MEDI3414 is a monovalent live attenuated intranasal vaccine developed for the prevention of infection with the Influenza A/H1N1 virus. It is administered as a nasal spray and does not contain preservatives or adjuvants. The vaccine works by introducing a weakened form of the H1N1 virus to stimulate an immune response without causing disease, thereby providing immunity against future infections with this strain. The primary indication is prophylaxis against pandemic H1N1 influenza infection. The developer of this vaccine is AstraZeneca[1][2].

Other names: Live attenuated nasal spray vaccine for H1N1Monovalent live attenuated pandemic influenza vaccine

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on MEDI3414.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI3414.

Explore the full profile